BRNS vs. CMRX, ONCY, IFRX, SLS, YS, CUE, SPRO, ACRS, VTVT, and ANVS
Should you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Chimerix (CMRX), Oncolytics Biotech (ONCY), InflaRx (IFRX), SELLAS Life Sciences Group (SLS), YS Biopharma (YS), Cue Biopharma (CUE), Spero Therapeutics (SPRO), Aclaris Therapeutics (ACRS), vTv Therapeutics (VTVT), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical preparations" industry.
Barinthus Biotherapeutics (NASDAQ:BRNS) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking.
In the previous week, Barinthus Biotherapeutics and Barinthus Biotherapeutics both had 4 articles in the media. Barinthus Biotherapeutics' average media sentiment score of 1.44 beat Chimerix's score of 1.02 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.
25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 45.4% of Chimerix shares are held by institutional investors. 8.0% of Barinthus Biotherapeutics shares are held by company insiders. Comparatively, 13.1% of Chimerix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Barinthus Biotherapeutics has higher revenue and earnings than Chimerix. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.
Barinthus Biotherapeutics has a beta of -0.45, indicating that its stock price is 145% less volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Chimerix received 380 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 63.80% of users gave Chimerix an outperform vote.
Barinthus Biotherapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 253.98%. Chimerix has a consensus target price of $8.50, suggesting a potential upside of 808.61%. Given Chimerix's higher possible upside, analysts plainly believe Chimerix is more favorable than Barinthus Biotherapeutics.
Barinthus Biotherapeutics has a net margin of 0.00% compared to Chimerix's net margin of -25,337.96%. Barinthus Biotherapeutics' return on equity of -36.61% beat Chimerix's return on equity.
Summary
Chimerix beats Barinthus Biotherapeutics on 8 of the 15 factors compared between the two stocks.
Get Barinthus Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Barinthus Biotherapeutics Competitors List
Related Companies and Tools
